Graybug Vision Competitors, Revenue, Alternatives and Pricing

Claim your profile


Total Funding:N/A
Lead Investor(s):N/A

City Ranking

Industry Ranking

State Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Graybug Vision's estimated annual revenue is currently $9.4M per year.(?)
  • Graybug Vision's estimated revenue per employee is $201,000

Employee Data

  • Graybug Vision has 47 Employees.(?)
  • Graybug Vision grew their employee count by 68% last year.
  • Graybug Vision currently has 1 job openings.

Graybug Vision was founded in September 2011 as a spin-out of the world-renowned Wilmer Eye Institute of the Johns Hopkins University School of Medicine. Graybug Vision is a clinical-stage pharmaceutical company focused on developing the next generation of products for the treatment of chronic vision-threatening diseases of the retina and optic nerve. Graybug Visionᅢᄁ¬ツᆲ¬トᄁs initial technology was co-developed by founder, Justin Hanes, PhD, who is the Lewis J. Ort Professor of Ophthalmology at the Wilmer Eye Institute of the Johns Hopkins University, in collaboration with co-founders and leading ophthalmology clinician-scientists from the Wilmer Eye Institute, Peter A. Campochiaro, MD and Peter J. McDonnell, MD. To address the burden of frequent intravitreal injections associated with managing patients with neovascular age-related macular degeneration (wet AMD), diabetic macular edema (DME), and retinal vascular occlusive disease (RVO), Graybug Vision is developing a proprietary depot formulation of sunitinib malate, GB-102. Sunitinib inhibits multiple biologic pathways known to be associated with angiogenesis, vascular permeability, fibrosis, while promoting neuroprotection to retinal ganglion cells and photoreceptors. To address the low compliance rate of self-administered eye drops for the treatment of elevated intraocular pressure (IOP) associated with primary open-angle glaucoma (POAG) and ocular hypertension (OHT), Graybug Vision is developing novel injectable compounds that will allow the physician to manage the pharmacologic treatment of disease rather than the patient. The company has established a portfolio of over 100 proprietary compounds to lower IOP and / or provide neuroprotection.